Lung cancer after treatment for Hodgkin's lymphoma: a systematic review
Developments in modern chemotherapy and radiotherapy mean that most patients with Hodgkin's lymphoma can now be cured. However, the long-term effects of anticancer treatment include an increased risk of a second malignant disease. We have done a systematic review of studies reporting long-term...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology 2005-10, Vol.6 (10), p.773-779 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 779 |
|---|---|
| container_issue | 10 |
| container_start_page | 773 |
| container_title | The lancet oncology |
| container_volume | 6 |
| creator | Lorigan, Paul Radford, John Howell, Anthony Thatcher, Nick |
| description | Developments in modern chemotherapy and radiotherapy mean that most patients with Hodgkin's lymphoma can now be cured. However, the long-term effects of anticancer treatment include an increased risk of a second malignant disease. We have done a systematic review of studies reporting long-term complications of the treatment of Hodgkin's lymphoma published in English since 1985. These studies show that risk of lung cancer is significantly increased in patients treated for Hodgkin's lymphoma, with a reported mean relative risk of 2·6–7·0 and a significantly increased absolute excess risk. The absolute excess risk increases with time from treatment, for as long as 20–25 years, and is highest in patients treated at age 45 years or older. Both chemotherapy and radiotherapy contribute to the risk, and evidence suggests that the effects are additive. Cigarette smoking seems to multiply the risk associated with both chemotherapy and radiotherapy. In the high-risk group of patients, 50–150 patients per 1000 are expected to develop lung cancer by 10–20 years after treatment. The role of screening in this group of patients has not yet been assessed, but an international study combining CT with genomic and proteomic assessment is planned. |
| doi_str_mv | 10.1016/S1470-2045(05)70387-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2063220453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204505703879</els_id><sourcerecordid>1662660281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-5e47e48d46e2b92e05d5062ee5bc627e41f81dc999d72e54f9e373a93c2b1bfa3</originalsourceid><addsrcrecordid>eNqFkM9PwyAUx4nRuPnjT9A0elAPVaBQihdjFt1MlnhQz4TS19m5thOoZv-9dFviyXjhEd7nfV_4IHRC8DXBJL15IUzgmGLGLzG_EjjJRCx30DA8s5izLNtd3zfIAB04N8eYCIL5PhqQlMhMZskQjaddM4uMbgzYSJc-nN6C9jU0PipbG03aYvZRNRcuWqzq5Xtb69tIR27lPNTaVyay8FXB9xHaK_XCwfG2HqK3x4fX0SSePo-fRvfT2LCM-ZgDE8CygqVAc0kB84LjlALw3KQ0tEiZkcJIKQtBgbNSQiISLRNDc5KXOjlE55vcpW0_O3BezdvONmGlojhNaP_bJFBnf1MEYymEDBDfQMa2zlko1dJWtbYrRbDqHau1Y9VHKszV2rHq50634V1eQ_E7tZUagLsNAEFEkGOVMxUEw0VlwXhVtNU_K34Apa2KFQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201009779</pqid></control><display><type>article</type><title>Lung cancer after treatment for Hodgkin's lymphoma: a systematic review</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Lorigan, Paul ; Radford, John ; Howell, Anthony ; Thatcher, Nick</creator><creatorcontrib>Lorigan, Paul ; Radford, John ; Howell, Anthony ; Thatcher, Nick</creatorcontrib><description>Developments in modern chemotherapy and radiotherapy mean that most patients with Hodgkin's lymphoma can now be cured. However, the long-term effects of anticancer treatment include an increased risk of a second malignant disease. We have done a systematic review of studies reporting long-term complications of the treatment of Hodgkin's lymphoma published in English since 1985. These studies show that risk of lung cancer is significantly increased in patients treated for Hodgkin's lymphoma, with a reported mean relative risk of 2·6–7·0 and a significantly increased absolute excess risk. The absolute excess risk increases with time from treatment, for as long as 20–25 years, and is highest in patients treated at age 45 years or older. Both chemotherapy and radiotherapy contribute to the risk, and evidence suggests that the effects are additive. Cigarette smoking seems to multiply the risk associated with both chemotherapy and radiotherapy. In the high-risk group of patients, 50–150 patients per 1000 are expected to develop lung cancer by 10–20 years after treatment. The role of screening in this group of patients has not yet been assessed, but an international study combining CT with genomic and proteomic assessment is planned.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(05)70387-9</identifier><identifier>PMID: 16198983</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Age ; Age Factors ; Antineoplastic Agents - adverse effects ; Breast cancer ; Cancer therapies ; Chemotherapy ; Child ; Child, Preschool ; Cigarette smoking ; Combined Modality Therapy - adverse effects ; Disease ; Drug dosages ; Female ; Follow-Up Studies ; Health risk assessment ; Hodgkin Disease - therapy ; Hodgkin's lymphoma ; Humans ; Infant ; Long-term effects ; Lung cancer ; Lung Neoplasms - etiology ; Lymphoma ; Male ; Middle Aged ; Neoplasms, Radiation-Induced ; Neoplasms, Second Primary - etiology ; Patients ; Population ; Proteomics ; Radiation therapy ; Risk Factors ; Risk groups ; Smoking - adverse effects ; Systematic review ; Tumors</subject><ispartof>The lancet oncology, 2005-10, Vol.6 (10), p.773-779</ispartof><rights>2005 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Oct 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-5e47e48d46e2b92e05d5062ee5bc627e41f81dc999d72e54f9e373a93c2b1bfa3</citedby><cites>FETCH-LOGICAL-c484t-5e47e48d46e2b92e05d5062ee5bc627e41f81dc999d72e54f9e373a93c2b1bfa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/201009779?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982,64370,64374,72224</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16198983$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lorigan, Paul</creatorcontrib><creatorcontrib>Radford, John</creatorcontrib><creatorcontrib>Howell, Anthony</creatorcontrib><creatorcontrib>Thatcher, Nick</creatorcontrib><title>Lung cancer after treatment for Hodgkin's lymphoma: a systematic review</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>Developments in modern chemotherapy and radiotherapy mean that most patients with Hodgkin's lymphoma can now be cured. However, the long-term effects of anticancer treatment include an increased risk of a second malignant disease. We have done a systematic review of studies reporting long-term complications of the treatment of Hodgkin's lymphoma published in English since 1985. These studies show that risk of lung cancer is significantly increased in patients treated for Hodgkin's lymphoma, with a reported mean relative risk of 2·6–7·0 and a significantly increased absolute excess risk. The absolute excess risk increases with time from treatment, for as long as 20–25 years, and is highest in patients treated at age 45 years or older. Both chemotherapy and radiotherapy contribute to the risk, and evidence suggests that the effects are additive. Cigarette smoking seems to multiply the risk associated with both chemotherapy and radiotherapy. In the high-risk group of patients, 50–150 patients per 1000 are expected to develop lung cancer by 10–20 years after treatment. The role of screening in this group of patients has not yet been assessed, but an international study combining CT with genomic and proteomic assessment is planned.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Age Factors</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cigarette smoking</subject><subject>Combined Modality Therapy - adverse effects</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Health risk assessment</subject><subject>Hodgkin Disease - therapy</subject><subject>Hodgkin's lymphoma</subject><subject>Humans</subject><subject>Infant</subject><subject>Long-term effects</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - etiology</subject><subject>Lymphoma</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms, Radiation-Induced</subject><subject>Neoplasms, Second Primary - etiology</subject><subject>Patients</subject><subject>Population</subject><subject>Proteomics</subject><subject>Radiation therapy</subject><subject>Risk Factors</subject><subject>Risk groups</subject><subject>Smoking - adverse effects</subject><subject>Systematic review</subject><subject>Tumors</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkM9PwyAUx4nRuPnjT9A0elAPVaBQihdjFt1MlnhQz4TS19m5thOoZv-9dFviyXjhEd7nfV_4IHRC8DXBJL15IUzgmGLGLzG_EjjJRCx30DA8s5izLNtd3zfIAB04N8eYCIL5PhqQlMhMZskQjaddM4uMbgzYSJc-nN6C9jU0PipbG03aYvZRNRcuWqzq5Xtb69tIR27lPNTaVyay8FXB9xHaK_XCwfG2HqK3x4fX0SSePo-fRvfT2LCM-ZgDE8CygqVAc0kB84LjlALw3KQ0tEiZkcJIKQtBgbNSQiISLRNDc5KXOjlE55vcpW0_O3BezdvONmGlojhNaP_bJFBnf1MEYymEDBDfQMa2zlko1dJWtbYrRbDqHau1Y9VHKszV2rHq50634V1eQ_E7tZUagLsNAEFEkGOVMxUEw0VlwXhVtNU_K34Apa2KFQ</recordid><startdate>200510</startdate><enddate>200510</enddate><creator>Lorigan, Paul</creator><creator>Radford, John</creator><creator>Howell, Anthony</creator><creator>Thatcher, Nick</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200510</creationdate><title>Lung cancer after treatment for Hodgkin's lymphoma: a systematic review</title><author>Lorigan, Paul ; Radford, John ; Howell, Anthony ; Thatcher, Nick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-5e47e48d46e2b92e05d5062ee5bc627e41f81dc999d72e54f9e373a93c2b1bfa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Age Factors</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cigarette smoking</topic><topic>Combined Modality Therapy - adverse effects</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Health risk assessment</topic><topic>Hodgkin Disease - therapy</topic><topic>Hodgkin's lymphoma</topic><topic>Humans</topic><topic>Infant</topic><topic>Long-term effects</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - etiology</topic><topic>Lymphoma</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms, Radiation-Induced</topic><topic>Neoplasms, Second Primary - etiology</topic><topic>Patients</topic><topic>Population</topic><topic>Proteomics</topic><topic>Radiation therapy</topic><topic>Risk Factors</topic><topic>Risk groups</topic><topic>Smoking - adverse effects</topic><topic>Systematic review</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lorigan, Paul</creatorcontrib><creatorcontrib>Radford, John</creatorcontrib><creatorcontrib>Howell, Anthony</creatorcontrib><creatorcontrib>Thatcher, Nick</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lorigan, Paul</au><au>Radford, John</au><au>Howell, Anthony</au><au>Thatcher, Nick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lung cancer after treatment for Hodgkin's lymphoma: a systematic review</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2005-10</date><risdate>2005</risdate><volume>6</volume><issue>10</issue><spage>773</spage><epage>779</epage><pages>773-779</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><coden>LANCAO</coden><abstract>Developments in modern chemotherapy and radiotherapy mean that most patients with Hodgkin's lymphoma can now be cured. However, the long-term effects of anticancer treatment include an increased risk of a second malignant disease. We have done a systematic review of studies reporting long-term complications of the treatment of Hodgkin's lymphoma published in English since 1985. These studies show that risk of lung cancer is significantly increased in patients treated for Hodgkin's lymphoma, with a reported mean relative risk of 2·6–7·0 and a significantly increased absolute excess risk. The absolute excess risk increases with time from treatment, for as long as 20–25 years, and is highest in patients treated at age 45 years or older. Both chemotherapy and radiotherapy contribute to the risk, and evidence suggests that the effects are additive. Cigarette smoking seems to multiply the risk associated with both chemotherapy and radiotherapy. In the high-risk group of patients, 50–150 patients per 1000 are expected to develop lung cancer by 10–20 years after treatment. The role of screening in this group of patients has not yet been assessed, but an international study combining CT with genomic and proteomic assessment is planned.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>16198983</pmid><doi>10.1016/S1470-2045(05)70387-9</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The lancet oncology, 2005-10, Vol.6 (10), p.773-779 |
| issn | 1470-2045 1474-5488 |
| language | eng |
| recordid | cdi_proquest_journals_2063220453 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Adolescent Adult Age Age Factors Antineoplastic Agents - adverse effects Breast cancer Cancer therapies Chemotherapy Child Child, Preschool Cigarette smoking Combined Modality Therapy - adverse effects Disease Drug dosages Female Follow-Up Studies Health risk assessment Hodgkin Disease - therapy Hodgkin's lymphoma Humans Infant Long-term effects Lung cancer Lung Neoplasms - etiology Lymphoma Male Middle Aged Neoplasms, Radiation-Induced Neoplasms, Second Primary - etiology Patients Population Proteomics Radiation therapy Risk Factors Risk groups Smoking - adverse effects Systematic review Tumors |
| title | Lung cancer after treatment for Hodgkin's lymphoma: a systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T16%3A10%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lung%20cancer%20after%20treatment%20for%20Hodgkin's%20lymphoma:%20a%20systematic%20review&rft.jtitle=The%20lancet%20oncology&rft.au=Lorigan,%20Paul&rft.date=2005-10&rft.volume=6&rft.issue=10&rft.spage=773&rft.epage=779&rft.pages=773-779&rft.issn=1470-2045&rft.eissn=1474-5488&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1470-2045(05)70387-9&rft_dat=%3Cproquest_cross%3E1662660281%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=201009779&rft_id=info:pmid/16198983&rft_els_id=S1470204505703879&rfr_iscdi=true |